These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


536 related items for PubMed ID: 18753116

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J, Lawal A, Pulido F, Soto-Malave R, Gathe J, Tian M, Fredrick LM, Podsadecki TJ, Nilius AM.
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
    Soriano V, Arastéh K, Migrone H, Lutz T, Opravil M, Andrade-Villanueva J, Antunes F, Di Perri G, Podzamczer D, Taylor S, Domingo P, Gellermann H, de Rossi L, ARTEN investigators.
    Antivir Ther; 2011; 16(3):339-48. PubMed ID: 21555816
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
    Mills A, Mildvan D, Podzamczer D, Fätkenheuer G, Leal M, Than S, Valluri SR, Craig C, McFadyen L, Vourvahis M, Heera J, Valdez H, Rinehart AR, Portsmouth S.
    J Acquir Immune Defic Syndr; 2013 Feb 01; 62(2):164-70. PubMed ID: 23187936
    [Abstract] [Full Text] [Related]

  • 13. Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine.
    DeJesus E, Ruane P, McDonald C, Garcia F, Sharma S, Corales R, Ravishankar J, Khanlou H, Shamblaw D, Ecker J, Ebrahimi R, Flaherty J, COMET Study Team.
    HIV Clin Trials; 2008 Feb 01; 9(2):103-14. PubMed ID: 18474495
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.
    Dejesus E, Mills A, Bhatti L, Conner C, Storfer S.
    Int J Clin Pract; 2011 Dec 01; 65(12):1240-9. PubMed ID: 21999631
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
    Dumond JB, Adams JL, Prince HM, Kendrick RL, Wang R, Jennings SH, Malone S, White N, Sykes C, Corbett AH, Patterson KB, Forrest A, Kashuba AD.
    HIV Med; 2013 Aug 01; 14(7):401-9. PubMed ID: 23433482
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.
    Vrouenraets SM, Wit FW, Fernandez Garcia E, Moyle GJ, Jackson AG, Allavena C, Raffi F, Jayaweera DT, Mauss S, Katlama C, Fisher M, Slama L, Hardy WD, Dejesus E, van Eeden A, Reiss P, BASIC Study Group.
    HIV Med; 2011 Nov 01; 12(10):620-31. PubMed ID: 21819530
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 27.